Browse studies

Find your next paid study

2,803 recruiting studies matching your filters

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with pla…

Chronic Kidney Disease

Estimated

~$10 – $7,500

AstraZenecaNCT07753993

Observational

Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans

The investigators aim to support care partner's well-being and satisfaction with VA care and decrease their work burden by offering extra support from a traine…

DementiaCancerRenal Disease+1 more

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT06963970

Phase 2

Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes

This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospi…

Sickle Cell Disease

Estimated

~$10 – $7,500

Inova Health Care ServicesNCT07023666

Phase 3

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and …

Pulmonary Disease, Chronic Obstructive

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07780669

Phase 4

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn's Disease (CD)

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together w…

An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)

This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim…

Connective Tissue Diseases

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06716606

Phase 1

A Phase I/II Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin…

Sickle Cell Disease

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06546670

Observational

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

The purpose of this study is to see if 6 months of home-based walking will improve memory, and brain structure and function, compared to health education in ol…

Mild Cognitive ImpairmentChronic Kidney Diseases

Estimated

~$10 – $6,250

Columbia UniversityNCT05655325

Phase 3

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease

This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with m…

Moderately to Severely Active Crohns Disease

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT07298421

Phase 2

The Alzheimer's Disease Tau Platform Clinical Trial

The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amy…

Preclinical Alzheimer's DiseaseAlzheimer DiseaseProdromal Alzheimer's Disease

Estimated

~$10 – $7,500

Paul S. AisenNCT06957418

Observational

Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening

The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preven…

Health Services AccessibilityRural HealthMedically Underserved Area+12 more

Estimated

~$10 – $7,500

William Brandenburg, MDNCT07669168

Phase 1

An Intravenous, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

Background: Heart disease is the leading cause of death, disability, and healthcare expense in the United States. Researchers think a new drug called Fx-5A ma…

Cardiovascular Disease

Estimated

~$10 – $5,625

National Heart, Lung, and Blood Institute (NHLBI)NCT04216342